» Articles » PMID: 14996737

Microarray Analysis Reveals Glucocorticoid-regulated Survival Genes That Are Associated with Inhibition of Apoptosis in Breast Epithelial Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Mar 5
PMID 14996737
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of the glucocorticoid receptor (GR) results in diverse physiological effects depending on cell type. For example, glucocorticoids (GC) cause apoptosis in lymphocytes but can rescue mammary epithelial cells from growth factor withdrawal-induced death. However, the molecular mechanisms of GR-mediated survival remain poorly understood. In this study, a large-scale oligonucleotide screen of GR-regulated genes was performed. Several of the genes that were found to be induced 30 min after GR activation encode proteins that function in cell survival signaling pathways. We also demonstrate that dexamethasone pretreatment of breast cancer cell lines inhibits chemotherapy-induced apoptosis in a GR-dependent manner and is associated with the transcriptional induction of at least two genes identified in our screen, serum and GC-inducible protein kinase-1 (SGK-1) and mitogen-activated protein kinase phosphatase-1 (MKP-1). Furthermore, GC treatment alone or GC treatment followed by chemotherapy increases both SGK-1 and MKP-1 steady-state protein levels. In the absence of GC treatment, ectopic expression of SGK-1 or MKP-1 inhibits chemotherapy-induced apoptosis, suggesting a possible role for these proteins in GR-mediated survival. Moreover, specific inhibition of SGK-1 or MKP-1 induction by the introduction of SGK-1- or MKP-1-small interfering RNA reversed the anti-apoptotic effects of GC treatment. Taken together, these data suggest that GR activation in breast cancer cells regulates survival signaling through direct transactivation of genes that encode proteins that decrease susceptibility to apoptosis. Given the widespread clinical administration of dexamethasone before chemotherapy, understanding GR-induced survival mechanisms is essential for achieving optimal therapeutic responses.

Citing Articles

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.

Chen N, Matossian M, Saha P, Rampurwala M, Kamaraju S, Hahn O Breast Cancer Res Treat. 2025; .

PMID: 39928262 DOI: 10.1007/s10549-025-07626-5.


Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.

Posani S, Gillis N, Lange C J Steroid Biochem Mol Biol. 2024; 243:106575.

PMID: 38950871 PMC: 11344665. DOI: 10.1016/j.jsbmb.2024.106575.


Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.

Taya M, Hou X, Veneris J, Kazi N, Larson M, Maurer M J Gynecol Oncol. 2024; 36(1):e4.

PMID: 38909640 PMC: 11790989. DOI: 10.3802/jgo.2025.36.e4.


Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.

Bennett L, Jaiswal P, Harkless R, Long T, Gao N, Vandenburg B Mol Cancer Ther. 2023; 23(4):552-563.

PMID: 38030378 PMC: 10985475. DOI: 10.1158/1535-7163.MCT-22-0479.


The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer.

Kirkby M, Popatia A, Lavoie J, Wang L Cancers (Basel). 2023; 15(19).

PMID: 37835396 PMC: 10571841. DOI: 10.3390/cancers15194702.